Stealth resubmits ultra-rare disease drug to FDA; Boehringer’s retinal dealnews2025-08-18T14:57:38+00:00August 18th, 2025|Endpoints News|
Neurizon cites ‘strain’ at FDA as reason for delay on IND hold; Fifty Years’ $126M fundnews2025-08-15T14:33:53+00:00August 15th, 2025|Endpoints News|
Aquestive’s $85M offering and royalty deal; Basilea gets rights to UTI drug candidatenews2025-08-14T14:32:53+00:00August 14th, 2025|Endpoints News|
Compass Therapeutics sells $120M in stock; RemeGen to seek China approvalnews2025-08-13T14:46:13+00:00August 13th, 2025|Endpoints News|
Biohaven scraps Phase 3 OCD program; Fosun’s licensing deal with Expedition news2025-08-12T13:57:47+00:00August 12th, 2025|Endpoints News|
Sitryx gets back rights to drug from Lilly deal; Humacyte is cutting costsnews2025-08-11T14:05:56+00:00August 11th, 2025|Endpoints News|
Ipsen is no longer advancing Sutro’s ADC; Layoffs at Tune Therapeuticsnews2025-08-08T14:44:08+00:00August 8th, 2025|Endpoints News|
XtalPi inks pact with Greg Verdine’s DoveTree; Regenxbio, AbbVie update dealnews2025-08-07T14:49:47+00:00August 7th, 2025|Endpoints News|
Terns seeks a partner for its oral metabolic programs; Jazz delays Phase 3 readoutnews2025-08-06T14:54:59+00:00August 6th, 2025|Endpoints News|
Shattuck Labs aims to raise $103M; Beijing biotech gets $55M in Series Dnews2025-08-05T14:35:52+00:00August 5th, 2025|Endpoints News|
